For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
What's new
...in the HealthProfessionals section of our website
- 2012-05-17 00:00:00: Monitoring for potential toxicity in patients with metal-on-metal hip prostheses: advice for health professionals
- 2012-05-01 00:00:00: About Clinical audit: Depression - challenges in primary care
- 2012-04-25 00:00:00: Nurse Update April 2012
More...
About Clinical e-Audit:CVD risk and lipid-modifying therapy About Clinical e-Audit: CVD risk and lipid-modifying therapy
|
This Clinical e-Audit provides GPs with the opportunity to assess absolute CVD risk, discuss risk with patients, consider prescribing lipid-modifying drugs for those at increased risk, and assess adherence. |
 |
| This software is designed for use on Microsoft Windows XP, Vista or Windows 7 operating systems. |
Benefits of NPS Clinical e-Audits
- quick and easy to complete
- free and independent quality improvement activity
- evidence-based clinical guidance and patient resources
- secure data transmission
- immediate individualised feedback
- compare improvements in your practice against best practice clinical indicators and your peers
Review 10 patients
- aged 45 years and above, or if Aboriginal/Torres Strait Islander aged 35 years and above, and
- with one or more risk factors for CVD
Participation will assist GPs to...
- Implement a systematic approach to identify patients for assessment of absolute cardiovascular disease risk.
- Recognise the benefits of discussing absolute cardiovascular risk and using a risk tool when providing advice on relevant lifestyle modification.
- Initiate lipid-modifying drugs for patients at increased absolute cardiovascular risk.
- Clarify the role of ezetimibe in reducing cardiovascular risk.
- Assess adherence to lipid-modifying drugs and lifestyle changes during regular consultations with patients.
|
|
|
Date published: 2010-10-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
